Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1994 Oct;94(4):1524–1532. doi: 10.1172/JCI117493

Adenosine-mediated inhibition of platelet aggregation by acadesine. A novel antithrombotic mechanism in vitro and in vivo.

D A Bullough 1, C Zhang 1, A Montag 1, K M Mullane 1, M A Young 1
PMCID: PMC295300  PMID: 7929829

Abstract

Inhibition of platelet aggregation by acadesine was evaluated both in vitro and ex vivo in human whole blood using impedance aggregometry, as well as in vivo in a canine model of platelet-dependent cyclic coronary flow reductions. In vitro, incubation of acadesine in whole blood inhibited ADP-induced platelet aggregation by 50% at 240 +/- 60 microM. Inhibition of platelet aggregation was time dependent and was prevented by the adenosine kinase inhibitor, 5'-deoxy 5-iodotubercidin, which blocked conversion of acadesine to its 5'-monophosphate, ZMP, and by adenosine deaminase. Acadesine elevated platelet cAMP in whole blood, which was also prevented by adenosine deaminase. In contrast, acadesine had no effect on ADP-induced platelet aggregation or platelet cAMP levels in platelet-rich plasma, but inhibition of aggregation was restored when isolated erythrocytes were incubated with acadesine before reconstitution with platelet-rich plasma. Acadesine (100 mg/kg i.v.) administered to human subjects also inhibited platelet aggregation ex vivo in whole blood. In the canine Folts model of platelet thrombosis, acadesine (0.5 mg/kg per min, i.v.) abolished coronary flow reductions, and this activity was prevented by pretreatment with the adenosine receptor antagonist, 8-sulphophenyltheophylline. These results demonstrate that acadesine exhibits antiplatelet activity in vitro, ex vivo, and in vivo through an adenosine-dependent mechanism. Moreover, the in vitro studies indicate that inhibition of platelet aggregation requires the presence of erythrocytes and metabolism of acadesine to acadesine monophosphate (ZMP).

Full text

PDF
1524

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbate R., Favilla S., Boddi M., Costanzo G., Prisco D. Factors influencing platelet aggregation in whole blood. Am J Clin Pathol. 1986 Jul;86(1):91–96. doi: 10.1093/ajcp/86.1.91. [DOI] [PubMed] [Google Scholar]
  2. Azuma H., Takashima Y., Ishikawa M., Yamakado T. Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro. Jpn J Pharmacol. 1984 Feb;34(2):159–170. doi: 10.1254/jjp.34.159. [DOI] [PubMed] [Google Scholar]
  3. BORN G. V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962 Jun 9;194:927–929. doi: 10.1038/194927b0. [DOI] [PubMed] [Google Scholar]
  4. Baggott J. E., Vaughn W. H., Hudson B. B. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J. 1986 May 15;236(1):193–200. doi: 10.1042/bj2360193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Barankiewicz J., Jimenez R., Ronlov G., Magill M., Gruber H. E. Alteration of purine metabolism by AICA-riboside in human B lymphoblasts. Arch Biochem Biophys. 1990 Nov 1;282(2):377–385. doi: 10.1016/0003-9861(90)90132-i. [DOI] [PubMed] [Google Scholar]
  6. Bolling S. F., Groh M. A., Mattson A. M., Grinage R. A., Gallagher K. P. Acadesine (AICA-riboside) improves postischemic cardiac recovery. Ann Thorac Surg. 1992 Jul;54(1):93–98. doi: 10.1016/0003-4975(92)91148-3. [DOI] [PubMed] [Google Scholar]
  7. Cardinal D. C., Flower R. J. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods. 1980 Feb;3(2):135–158. doi: 10.1016/0160-5402(80)90024-8. [DOI] [PubMed] [Google Scholar]
  8. Davies L. P., Jamieson D. D., Baird-Lambert J. A., Kazlauskas R. Halogenated pyrrolopyrimidine analogues of adenosine from marine organisms: pharmacological activities and potent inhibition of adenosine kinase. Biochem Pharmacol. 1984 Feb 1;33(3):347–355. doi: 10.1016/0006-2952(84)90225-9. [DOI] [PubMed] [Google Scholar]
  9. Dawicki D. D., Agarwal K. C., Parks R. E., Jr Adenosine metabolism in human whole blood. Effects of nucleoside transport inhibitors and phosphate concentration. Biochem Pharmacol. 1988 Feb 15;37(4):621–626. doi: 10.1016/0006-2952(88)90134-7. [DOI] [PubMed] [Google Scholar]
  10. Dawicki D. D., Agarwal K. C., Parks R. E., Jr Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233. Thromb Res. 1986 Jul 15;43(2):161–175. doi: 10.1016/0049-3848(86)90057-5. [DOI] [PubMed] [Google Scholar]
  11. Dawicki D. D., Agarwal K. C., Parks R. E., Jr Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine. Biochem Pharmacol. 1985 Nov 15;34(22):3965–3972. doi: 10.1016/0006-2952(85)90373-9. [DOI] [PubMed] [Google Scholar]
  12. Dixon R., Fujitaki J., Chrastil L., Lee J. AICA-riboside: direct quantitation in ultrafiltrates of plasma by HPLC during pharmacokinetic studies in man. Res Commun Chem Pathol Pharmacol. 1989 Sep;65(3):405–408. [PubMed] [Google Scholar]
  13. Dixon R., Gourzis J., McDermott D., Fujitaki J., Dewland P., Gruber H. AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. J Clin Pharmacol. 1991 Apr;31(4):342–347. doi: 10.1002/j.1552-4604.1991.tb03715.x. [DOI] [PubMed] [Google Scholar]
  14. Edlund A., Sidén A., Sollevi A. Evidence for an anti-aggregatory effect of adenosine at physiological concentrations and for its role in the action of dipyridamole. Thromb Res. 1987 Jan 15;45(2):183–190. doi: 10.1016/0049-3848(87)90172-1. [DOI] [PubMed] [Google Scholar]
  15. FitzGerald G. A. Dipyridamole. N Engl J Med. 1987 May 14;316(20):1247–1257. doi: 10.1056/NEJM198705143162005. [DOI] [PubMed] [Google Scholar]
  16. Galiñanes M., Bullough D., Mullane K. M., Hearse D. J. Sustained protection by acadesine against ischemia- and reperfusion-induced injury. Studies in the transplanted rat heart. Circulation. 1992 Aug;86(2):589–597. doi: 10.1161/01.cir.86.2.589. [DOI] [PubMed] [Google Scholar]
  17. Galiñanes M., Mullane K. M., Bullough D., Hearse D. J. Acadesine and myocardial protection. Studies of time of administration and dose-response relations in the rat. Circulation. 1992 Aug;86(2):598–608. doi: 10.1161/01.cir.86.2.598. [DOI] [PubMed] [Google Scholar]
  18. Gresele P., Arnout J., Deckmyn H., Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost. 1986 Feb 28;55(1):12–18. [PubMed] [Google Scholar]
  19. Gruber H. E., Hoffer M. E., McAllister D. R., Laikind P. K., Lane T. A., Schmid-Schoenbein G. W., Engler R. L. Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury. Circulation. 1989 Nov;80(5):1400–1411. doi: 10.1161/01.cir.80.5.1400. [DOI] [PubMed] [Google Scholar]
  20. Haslam R. J., McClenaghan M. D. Measurement of circulating prostacyclin. Nature. 1981 Jul 23;292(5821):364–366. doi: 10.1038/292364a0. [DOI] [PubMed] [Google Scholar]
  21. Haslam R. J., Vanderwel M. Measurement of changes in platelet cyclic AMP in vitro and in vivo by prelabeling techniques: application to the detection and assay of circulating PGI2. Methods Enzymol. 1989;169:455–471. doi: 10.1016/0076-6879(89)69081-7. [DOI] [PubMed] [Google Scholar]
  22. Heptinstall S., Fox S., Crawford J., Hawkins M. Inhibition of platelet aggregation in whole blood by dipyridamole and aspirin. Thromb Res. 1986 Apr 15;42(2):215–223. doi: 10.1016/0049-3848(86)90297-5. [DOI] [PubMed] [Google Scholar]
  23. Hourani S. M., Cusack N. J. Pharmacological receptors on blood platelets. Pharmacol Rev. 1991 Sep;43(3):243–298. [PubMed] [Google Scholar]
  24. Ingerman-Wojenski C., Smith J. B., Silver M. J. Evaluation of electrical aggregometry: comparison with optical aggregometry, secretion of ATP, and accumulation of radiolabeled platelets. J Lab Clin Med. 1983 Jan;101(1):44–52. [PubMed] [Google Scholar]
  25. Iskandrian A. S. Myocardial ischemia during pharmacological stress testing. Circulation. 1993 Apr;87(4):1415–1417. doi: 10.1161/01.cir.87.4.1415. [DOI] [PubMed] [Google Scholar]
  26. Johnson G. J., Leis L. A., Francis G. S. Adenosine potentiates the inhibitory effects of calcium channel antagonists on human platelet aggregation induced by thromboxane A2 or U46619. Thromb Res. 1990 Jul 1;59(1):139–148. doi: 10.1016/0049-3848(90)90279-l. [DOI] [PubMed] [Google Scholar]
  27. Kitakaze M., Hori M., Sato H., Takashima S., Inoue M., Kitabatake A., Kamada T. Endogenous adenosine inhibits platelet aggregation during myocardial ischemia in dogs. Circ Res. 1991 Nov;69(5):1402–1408. doi: 10.1161/01.res.69.5.1402. [DOI] [PubMed] [Google Scholar]
  28. Marangos P. J., Loftus T., Wiesner J., Lowe T., Rossi E., Browne C. E., Gruber H. E. Adenosinergic modulation of homocysteine-induced seizures in mice. Epilepsia. 1990 May-Jun;31(3):239–246. doi: 10.1111/j.1528-1157.1990.tb05371.x. [DOI] [PubMed] [Google Scholar]
  29. Möser G. H., Schrader J., Deussen A. Turnover of adenosine in plasma of human and dog blood. Am J Physiol. 1989 Apr;256(4 Pt 1):C799–C806. doi: 10.1152/ajpcell.1989.256.4.C799. [DOI] [PubMed] [Google Scholar]
  30. Riess H., Braun G., Brehm G., Hiller E. Critical evaluation of platelet aggregation in whole human blood. Am J Clin Pathol. 1986 Jan;85(1):50–56. doi: 10.1093/ajcp/85.1.50. [DOI] [PubMed] [Google Scholar]
  31. Rowe G. G., Folts J. D. Aspirin and dipyridamole and their limitations in the therapy of coronary artery disease. Clin Cardiol. 1990 Mar;13(3):165–170. doi: 10.1002/clc.4960130304. [DOI] [PubMed] [Google Scholar]
  32. Sabina R. L., Patterson D., Holmes E. W. 5-Amino-4-imidazolecarboxamide riboside (Z-riboside) metabolism in eukaryotic cells. J Biol Chem. 1985 May 25;260(10):6107–6114. [PubMed] [Google Scholar]
  33. Saniabadi A. R., Tomiak R. H., Lowe G. D., Barbenel J. C., Forbes C. D. Dipyridamole inhibits red cell-induced platelet activation. Atherosclerosis. 1989 Apr;76(2-3):149–154. doi: 10.1016/0021-9150(89)90098-1. [DOI] [PubMed] [Google Scholar]
  34. Sollevi A. Cardiovascular effects of adenosine in man; possible clinical implications. Prog Neurobiol. 1986;27(4):319–349. doi: 10.1016/0301-0082(86)90005-5. [DOI] [PubMed] [Google Scholar]
  35. Wallenstein S., Zucker C. L., Fleiss J. L. Some statistical methods useful in circulation research. Circ Res. 1980 Jul;47(1):1–9. doi: 10.1161/01.res.47.1.1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES